Amyloid beta-peptide (Abeta) is central to the pathogenesis of Alzheimer's disease (AD), and the AD brain is under extensive oxidative stress. Previous research from our laboratory combined these two observations into a model for neurodegeneration in AD, a model based on Abeta-associated free radical oxidative stress. In neurons, Abeta-associated free radical oxidative stress and toxicity depend critically on methionine residue 35 of Abeta(1-42), and both are prevented or modulated by exogenous antioxidants. We have used the emerging techniques of proteomics, coupled with immunoblottmg methods, to identify specifically oxidatively modified proteins in AD brain. We now propose to extend these observations to sporadic and inherited AD and rodent models thereof to gain insight into the mechanisms of Abeta (1-42) in the oxidative stress and neurotoxic properties of this peptide.
In Specific Aim # 1, we will use proteomics to test the hypothesis that there will be a common set of oxidized proteins in inherited and sporadic AD that differ from those of normal aging, and that these oxidized proteins in common are important in the pathogenesis of AD. Similar studies in mice models of inherited AD are hypothesized to lead to the identity of the same common proteins.
In Specific Aim #2, we will test the hypothesis that mitochondrial dysfunction and Ca 2+ accumulation in brain from genetic mutations relevant to AD will be found in adult brain mitochondria from the model chosen in Specific Aim #1 compared to adult brain from wild-type mice. Those proteins identified by proteomics in the systems studied will be expressed in SY5Y cells and challenged with Abeta(1-42) to determine if there is increased vulnerability to oxidative stress, mitochondrial dysfunction, Ca 2+ accumulation, and cytotoxicity.
In Specific Aim #3, we will use proteomics to test the hypothesis that Abeta(1-42)-induced oxidative stress in embryonic neuronal cultures obtained from the rodent model of familial AD chosen in Specific Aim # 1 leads to the same oxidatively modified proteins as exists in adult brain from this animal and in human familial AD brain.
In Specific Aim #4, we will investigate whether oxidative stress induces mitochondrial alterations in neuronal cultures obtained from the rodent model of inherited AD chosen in Specific Aim #1, or whether mitochondrial alterations induced in these cultures leads to oxidative stress.
In Specific Aim # 5, we will test the hypothesis that endogenous or exogenous antioxidants protect brain in-vivo against oxidative stress in the rodent model chosen in Specific Aim # 1. This is a comprehensive set of proposed studies, employing novel approaches in systems ranging from sporadic and inherited AD brain, to genetic animal models of AD, to neuronal cultures, designed to gain insight into Abeta-associated free radical oxidative stress and neurotoxicity and their modulation by endogenous and exogenous antioxidants. The increased understanding that will result from these studies will provide insight into potential therapeutic interventions in this important dementing disorder that affects millions of Americans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010836-13
Application #
7274271
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
13
Fiscal Year
2006
Total Cost
$277,488
Indirect Cost
Name
University of Kentucky
Department
Type
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Butterfield, D Allan; Palmieri, Erika M; Castegna, Alessandra (2016) Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics 13:259-74
Chen, Chun-Hau; Li, Wenzong; Sultana, Rukhsana et al. (2015) Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis 76:13-23
Barone, Eugenio; Di Domenico, Fabio; Butterfield, D Allan (2014) Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 88:605-16
Cenini, Giovanna; Fiorini, Ada; Sultana, Rukhsana et al. (2014) An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic Biol Med 76:89-95
Barone, Eugenio; Di Domenico, Fabio; Mancuso, Cesare et al. (2014) The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol Dis 62:144-59
Förster, Sarah; Welleford, Andrew S; Triplett, Judy C et al. (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim Biophys Acta 1842:1333-9
Swomley, Aaron M; Förster, Sarah; Keeney, Jierel T et al. (2014) Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta 1842:1248-57
Latimer, Caitlin S; Brewer, Lawrence D; Searcy, James L et al. (2014) Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci U S A 111:E4359-66
Butterfield, D Allan; Di Domenico, Fabio; Barone, Eugenio (2014) Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta 1842:1693-706
Perluigi, Marzia; Di Domenico, Fabio; Buttterfield, D Allan (2014) Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl 8:73-85

Showing the most recent 10 out of 356 publications